Sept 11 (Reuters) - Moderna said on Monday it is collaborating with Immatics to develop cancer vaccines.
Immatics will get $120 million upfront cash as part of the agreement. (Reporting by Christy Santhosh in Bengaluru; Editing by Shounak Dasgupta)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.44 USD | +8.21% | +16.36% | +27.64% |
May. 15 | Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating | MT |
May. 14 | Immatics' Q1 Loss Narrows. Revenue Rises | MT |
Sept 11 (Reuters) - Moderna said on Monday it is collaborating with Immatics to develop cancer vaccines.
Immatics will get $120 million upfront cash as part of the agreement. (Reporting by Christy Santhosh in Bengaluru; Editing by Shounak Dasgupta)
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
154.8 USD | +6.54% | +4.68% | 55.7B | ||
13.44 USD | +8.21% | +16.36% | 1.28B | ||
1st Jan change | Capi. | |
---|---|---|
+27.64% | 1.28B | |
+18.72% | 123B | |
+14.53% | 107B | |
-2.88% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-11.83% | 16.23B | |
+1.46% | 13.43B | |
+24.22% | 11.32B |